Develop iPSC-derived microglia to treat progranulin-deficient Frontotemporal Dementia
Grant Award Details
Grant Type:
Grant Number:
DISC2-11165
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Cell Line Generation:
Award Value:
$1,547,157
Status:
Closed
Grant Application Details
Application Title:
Develop iPSC-derived microglia to treat progranulin-deficient Frontotemporal Dementia
Public Abstract:
Research Objective
Develop stem cell-based therapy to treat dementia
Impact
There are no treatments for dementia. If successfully achieved, this study will lead to a cure of a familial form of dementia in the elderly population.
Major Proposed Activities
Develop stem cell-based therapy to treat dementia
Impact
There are no treatments for dementia. If successfully achieved, this study will lead to a cure of a familial form of dementia in the elderly population.
Major Proposed Activities
- Develop a robust human stem cell-derived microglial platform for cell-based therapy
- Determine short-term safety and efficacy of engrafted human microglia in wildtype mice
- Determine short-term efficacy of engrafted human microglia in FTD mouse models
- Determine long-term efficacy of engrafted human microglia in FTD mouse models
Statement of Benefit to California:
The proposed research will benefit the State of California and its citizens because of the potential to cure
a major form of dementia in the elderly population. With the fast aging population in California, more and
more Californians are diagnosed with neurodegenerative dementias.
There is an urgent need to develop a treatment or cure for these devastating conditions. Success of our
study will address this urgent medical challenge of our modern society.
